Calcium Resonium
- Name:
Calcium Resonium
- Company:
SANOFI
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 06/07/20
(Click to Download)Click on this link to Download PDF directly
SANOFI
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 6 July 2020 PIL
Reasons for updating
- XPIL Removed
Updated on 5 February 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - use in children and adolescents
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 2 - driving and using machines
- Change to section 2 - excipient warnings
- Change to section 3 - dose and frequency
- Change to section 3 - use in children/adolescents
- Change to section 3 - how to take/use
- Change to section 3 - duration of treatment
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
Updated on 11 January 2019 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Oral
The usual dose is 15g, 3 to 4 times a day. The resin is given by mouth in a little water, or it may be made into a paste with some sweetened vehicle.
Administer Calcium Resonium at least 3 hours before or 3 hours after other oral medications. For
patients with gastroparesis, a 6-hour separation should be considered1 (see Section 4.4 and Section
4.5).
-
- Special warnings and special precautions for use
Binding to other orally administered medications: Calcium Resonium may bind to orally administered medications, which could decrease their gastrointestinal absorption and efficacy. Avoid co-administration of Calcium Resonium with other orally administered medications. Administer Calcium Resonium at least 3 hours before or 3 hours after other oral medications. For patients with gastroparesis, a 6-hour separation should be considered (see Section 4.2 and Section 4.5).
- Special warnings and special precautions for use
4.5 Interaction with other medicinal products and other forms of interaction
Concomitant use not recommended
Orally administered medications: Calcium Resonium has the potential to bind to other orally administered medications. Binding of Calcium Resonium to other oral medications could cause decrease in their gastrointestinal absorption and efficacy. Dosing separation of Calcium Resonium from other orally administered medications is recommended (see Section 4.2 and Section 4.4).
Updated on 1 July 2014 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 1 July 2014 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.5: 'other serious gastrointestinal adverse reactions' included.
Section 4.8: Gastrointestinal disorders updated.
Section 4.9: to include '(potassium, calcium)'.
Updated on 7 February 2013 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 4 February 2013 PIL
Reasons for updating
- New PIL for new product
Updated on 4 February 2013 PIL
Reasons for updating
- Change of manufacturer
- Change to warnings or special precautions for use
Updated on 4 May 2011 PIL
Reasons for updating
- Improved electronic presentation
Updated on 6 August 2010 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Change to Section 4.4 - Special warnings and special precautions for use. Changes made to bring in line with company core data sheet
Change to Section 4.5 - Interactions with other medicinal productions and other forms of interaction. Changes made to bring in line with company core data sheet.
Change to Section 4.8 - Undesirable effects. Changes made to bring in line with company core data sheet.
Updated on 5 August 2010 PIL
Reasons for updating
- Change to side-effects
- Change to improve clarity and readability
Updated on 4 December 2009 PIL
Reasons for updating
- Change due to user-testing of patient information
Updated on 15 December 2008 SmPC
Reasons for updating
- Correction of spelling/typing errors
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 5 September 2008 PIL
Reasons for updating
- Change to marketing authorisation holder
Updated on 5 September 2008 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 25 July 2008 SmPC
Reasons for updating
- Improved electronic presentation
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 27 August 2007 PIL
Reasons for updating
- Improved electronic presentation
Updated on 9 August 2007 PIL
Reasons for updating
- Improved electronic presentation
Updated on 18 December 2006 PIL
Reasons for updating
- Improved electronic presentation
Updated on 28 July 2005 PIL
Reasons for updating
- Improved electronic presentation
Updated on 26 April 2005 SmPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.2 - Incompatibilities
- Change to section 6.4 - Special precautions for storage
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 21 October 2004 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 1 July 2003 SmPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 26 June 2003 SmPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)